levetiracetam Side Effects
Also known as: Keppra
Analysis of 127,698 adverse event reports submitted to the FDA from 2002 to 2025.
Total Reports
127,698
Death-Related
11,586
9.1% of reports
Hospitalizations
47,411
37.1% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 11,586 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 3,119 |
| OFF LABEL USE | 962 |
| DRUG INEFFECTIVE | 712 |
| TOXICITY TO VARIOUS AGENTS | 637 |
| SEIZURE | 635 |
| PNEUMONIA | 618 |
| COMPLETED SUICIDE | 581 |
| CARDIAC ARREST | 492 |
| SEPSIS | 477 |
| DISEASE PROGRESSION | 426 |
| RESPIRATORY FAILURE | 393 |
| STATUS EPILEPTICUS | 348 |
| PYREXIA | 347 |
| MULTIPLE ORGAN DYSFUNCTION SYNDROME | 342 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 336 |
| MALIGNANT NEOPLASM PROGRESSION | 315 |
| DIARRHOEA | 312 |
| CARDIO-RESPIRATORY ARREST | 303 |
| THROMBOCYTOPENIA | 293 |
| FATIGUE | 292 |
Reactions in Hospitalization Reports
Top reactions in 47,411 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| SEIZURE | 5,820 |
| DRUG INEFFECTIVE | 3,823 |
| OFF LABEL USE | 3,317 |
| FALL | 2,315 |
| PYREXIA | 2,071 |
| PNEUMONIA | 1,983 |
| FATIGUE | 1,822 |
| CONVULSION | 1,730 |
| VOMITING | 1,721 |
| SOMNOLENCE | 1,655 |
| DRUG INTERACTION | 1,642 |
| STATUS EPILEPTICUS | 1,609 |
| CONFUSIONAL STATE | 1,564 |
| EPILEPSY | 1,491 |
| DIARRHOEA | 1,476 |
| HEADACHE | 1,458 |
| NAUSEA | 1,453 |
| ASTHENIA | 1,338 |
| DIZZINESS | 1,284 |
| CONDITION AGGRAVATED | 1,264 |
Nearby — Related Medications
What the FAERS Data Reveals About levetiracetam Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 127,698 voluntary reports linked to levetiracetam and its brand equivalents (Keppra), spanning 2002 through 2025. Of those, 11,586 (9.1%) listed death as an outcome and 47,411 (37.1%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 55% were female and 45% male; age distribution skews toward 18-44, with 24,199 reports in that bracket. The single most reported reaction is seizure with 15,308 submissions, followed by drug ineffective and off label use.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.